AlzeCure is part of the region’s world-leading research in healthy aging

Invest Stockholm has now updated its presentation of the region’s research and the companies working with neurodegenerative diseases. Here you will find, among others, AlzeCure, which is developing a painkiller based on this year’s Nobel Prize in Medicine.

Stockholm-Uppsala holds world-leading knowledge in the field of healthy aging. Invest Stockholm has made an extensive review of the region’s academic research in an updated report that also includes several selected companies.

Here is one of Flemingsberg’s knowledge companies: AlzeCure, which develops new innovative drug therapies for the treatment of severe diseases that affect the central nervous system, such as Alzheimer’s disease and pain.

The company is developing a painkiller based on a discovery by David Julius and Ardem Patapoutian who share this year’s Nobel Prize in Physiology or Medicine.

Read more about AlzeCure and the region’s leading research in the report: Improving Quality of Life for People with Neurodegenerative Diseases (pdf).

A strategy, a plan, but above all, action!

The Flemingsberg Science Foundation board approved its business plan for 2022 in January. This essentially paves the way for an increase in the pace of business set-ups and opportunities to innovate in Flemingsberg. Almost six months on, what have we achieved?

Do you want to know more?
Subscribe to our newsletter.

SUBSCRIBE

Do you want to know more?
Subscribe to our newsletter.

SUBSCRIBE
CF_logo_neg
2021-12-10T13:19:20+01:00
Go to Top